Pfizer Doubles Down on AI/ML to Bring Transformative Medicines to Patients

Artificial intelligence and machine learning (AI/ML) are key to enabling drug discovery and development, and Pfizer is leading the biopharma industry into the next wave of innovation. The company is rapidly scaling up and recruiting talent for a collaborative effort intended to get transformative medicines to patients faster. The mandate is "uncompromising and extremely high-quality science," Sandeep Menon, chief scientific officer, AI digital sciences, SVP and head of early clinical development told BioSpace. The vision is three-fold: uncover disease biology with AI; use these insights to design the right molecules; determine the right patient population for clinical trial success. "We're building the next generation of tools to use across the preclinical and clinical development spectrum," said Jared Christensen, vice president and head of early clinical development, clinical AI/ML and quantitative sciences.